Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsHealth Net leuprolide coverage update | OpenPayer
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    ModifiedHealth NetPolicy CP PHAR.173

    Leuprolide acetate and leuprolide mesylate coverage

    Customize your policy alerts

    Sign up for Health Net Policy CP PHAR.173 alerts

    Get alerted when Policy CP PHAR.173 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines medical necessity and prior authorization criteria for leuprolide acetate (Eligard, Fensolvi, Lupron Depot, Lupron Depot-Ped) and leuprolide mesylate (Camcevi) for Health Net (Medicaid) members.

    Policy Summary
    PayerHealth Net
    PolicyLeuprolide acetate and leuprolide mesylate coverage
    Policy CodePolicy CP PHAR.173
    Change TypeClinical and operational updates (HCPCS additions, redirection rules, dosing/age and duration revisions)
    Effective DateOct 1, 2024
    Last ReviewNov 24, 2024
    Next Review DateN/A
    Key ActionSubmit prior authorization with supporting documentation demonstrating member meets indication-specific criteria and required attestations (e.g., state regulation attestation for transgender-related care).
    SourceLink
    POLICY UPDATE CHANGES

    Added HCPCS codes for Fensolvi and Camcevi; modified commercial approval duration to 6 months or member's renewal date for certain indications.

    Added Appendix F listing states with regulations against redirections in cancer and added redirection to Eligard for Lupron Depot prostate cancer requests through the pharmacy benefit.

    For uterine fibroids, Lupron Depot must be prescribed concurrently with iron therapy and commercial approval duration revised to 3 months.

    Added new 45 mg dosage form for a 6-month Lupron Depot‑Ped dosing regimen.

    For gender dysphoria/transition, added requirement for provider attestation of understanding current state regulations and that such care is coverable under those regulations.

    Commercial and HIM lines of business were removed from this policy; separate policy will be created.

    MultipleHCPCS codes referenced
    Camcevi, FensolviProducts added
    3–6 moCommercial approval durations
    30 daysMinimum prior exposure for continuation
    45 mg (6‑mo)New pediatric dose

    Coverage Criteria

    inv-01: Initial Therapy

    Covered when ALL of the following are met for each specific indication

    Prostate cancer (Initial): 1. Diagnosis of prostate cancer; 2. Prescribed by or in consultation with an oncologist or urologist; 3. Age > 18 years; 4. Requested product is one of the covered formulations (leuprolide acetate injection; Camcevi; Eligard; Lupron Depot); 5. For Lupron Depot requests through the pharmacy benefit, prior failure of Eligard is required unless contraindicated or clinically significant adverse effects are experienced; 6. Dosing limits: leuprolide acetate injection (SC) ≤ 1 mg/day; Eligard/Lupron Depot dosing limits not to exceed 7.5 mg per month, 22.5 mg per 3 months, 30 mg per 4 months, or 45 mg per 6 months; Camcevi (SC) ≤ 42 mg per 6 months; 7. If request is for an off-label dose, dose must be supported by practice guidelines or peer-reviewed literature (prescriber must submit supporting evidence).
    Endometriosis (Initial): 1. Diagnosis of endometriosis; 2. Request is for Lupron Depot (3.75 mg or 11.25 mg); 3. Prescribed by or in consultation with a gynecologist; 4. Age criteria: member ≥ 18 years OR < 18 years and postpubertal; 5. Either surgically confirmed endometriosis OR clinically suspected with failure within the last year of a 3‑month trial of one of the following (unless contraindicated or clinically significant adverse effects): (a) an NSAID, (b) an oral or injectable depot contraceptive, or (c) a progestin; 6. Total duration of leuprolide therapy for the current course has not exceeded 12 months; 7. Dose does not exceed 3.75 mg per month or 11.25 mg per 3 months.
    Policy Summary
    PayerHealth Net
    PolicyLeuprolide acetate and leuprolide mesylate coverage
    Policy CodePolicy CP PHAR.173
    Change TypeClinical and operational updates (HCPCS additions, redirection rules, dosing/age and duration revisions)
    Effective DateOct 1, 2024
    Last ReviewNov 24, 2024
    Next Review DateN/A
    Key ActionSubmit prior authorization with supporting documentation demonstrating member meets indication-specific criteria and required attestations (e.g., state regulation attestation for transgender-related care).
    SourceLink
    On This Page
    Coverage CriteriaCoding and BillingProvider Actions and RequirementsStep Therapy and Therapeutic AlternativesQuantity Limits and Formulation ConstraintsSite of Care and AdministrationBackgroundDefinitions
    Uterine Fibroids (Preoperative anemia) (Initial): 1. Diagnosis of anemia secondary to uterine leiomyomata confirmed by ultrasound; 2. Request is for Lupron Depot (3.75 mg or 11.25 mg); 3. Prescribed by or in consultation with a gynecologist; 4. Lupron Depot must be prescribed concurrently with iron therapy; 5. Intended use is preoperative to reduce fibroid size and improve hematologic control; 6. For members currently receiving treatment, total duration of therapy has not exceeded 3 months per treatment course; 7. Dose does not exceed 3.75 mg per month or 11.25 mg per 3 months.
    Central Precocious Puberty (CPP) (Initial): 1. Diagnosis of CPP confirmed by all of the following: (a) difference between bone age and chronological age > 1 year; (b) onset of secondary sex characteristics before age thresholds (female < 8 years; male < 9 years); (c) elevated hormones: basal LH > 0.2–0.3 mIU/mL and/or leuprolide‑stimulated LH > 3.3–5 IU/L (assay‑dependent); 2. Request is for one of: Fensolvi; leuprolide acetate injection (SC); Lupron Depot‑Ped (7.5, 11.25, 15, 30, 45 mg); 3. Prescribed by or in consultation with a pediatric endocrinologist; 4. Age requirements met per policy (female and male thresholds as above and policy age allowances); 5. Dose limits: diagnostic leuprolide acetate 20 mcg/kg as needed; therapeutic leuprolide acetate (SC) initial 50 mcg/kg/day with upward titration by 10 mcg/kg/day if down‑regulation not achieved; Fensolvi 45 mg per 6 months; Lupron Depot‑Ped dosing per weight/formulation (including 15 mg monthly, 30 mg/3 months, 45 mg/6 months as applicable).
    Breast or Ovarian Cancer (Off‑label) (Initial): 1. Diagnosis of hormone receptor‑positive breast cancer or ovarian cancer (including fallopian tube and primary peritoneal cancer); 2. Request is for Lupron Depot; 3. Prescribed by or in consultation with an oncologist; 4. Age > 18 years; 5. Dose limits: breast cancer not to exceed 3.75 mg per month or 11.25 mg per 3 months; ovarian cancer dosing limits described in policy (e.g., up to 7.5 mg per month or specified multi‑month regimens); 6. Off‑label dose/use must be supported by practice guidelines or peer‑reviewed literature (prescriber must submit supporting evidence).
    Gender Dysphoria / Gender Transition (Off‑label) (Initial): 1. Diagnosis of gender dysphoria or request for gender transition; 2. Prescribed by or in consultation with both an endocrinologist and a provider with expertise in transgender medicine (or appropriate mental health professional as specified); 3. For members < 18 years, member has reached or passed Tanner Stage 2; for members ≥ 18 years, requirements include failure to achieve physiologic hormone levels with gender‑affirming hormones unless contraindicated; 4. Psychosocial support/mental health follow‑up provided when psychiatric comorbidity exists; 5. Provider must attest understanding of current State regulations regarding transgender‑related health care and that such care is coverable under State regulations when applicable; 6. Dose must be within FDA maximum limits for any FDA‑approved indication or supported by guidelines/peer‑reviewed literature with prescriber evidence.
    Salivary Gland Tumors (Off‑label) (Initial): 1. Diagnosis of salivary gland tumor; 2. Prescribed by or in consultation with an oncologist; 3. Request is for Eligard or Lupron Depot; 4. Dose is within FDA maximum limits for any FDA‑approved indication or is supported by practice guidelines or peer‑reviewed literature for the off‑label use (prescriber must submit supporting evidence).

    inv-52: Initial Therapy (alternate grouping)

    Initial approval requires diagnosis-, prescriber-, age-, prior therapy-, and dosing-related criteria depending on indication.

    Diagnosis and prescriber requirements: 1. Member has one of the covered diagnoses (see indication‑specific nodes); 2. Prescription written by or in consultation with the appropriate specialist for the indication (e.g., oncologist, urologist, gynecologist, pediatric endocrinologist, transgender medicine expert);
    Age and maturation requirements: 1. Age requirements vary by indication (e.g., prostate cancer > 18 years; endometriosis or uterine fibroids allowed at age ≥ 18 when member is postpubertal or < 18 if postpubertal; CPP age thresholds per policy);
    Prior therapy / step requirements: 1. When applicable, prior therapy requirements apply (e.g., for Lupron Depot via pharmacy benefit, failure of Eligard is required unless contraindicated or clinically significant adverse effects occur; endometriosis requires prior trial of NSAID, contraceptive, or progestin unless contraindicated).
    Product and dosing limits: 1. Requested product must be a covered formulation (leuprolide acetate injection, Camcevi, Eligard, Lupron Depot, Lupron Depot‑Ped, Fensolvi); 2. Dosing must adhere to formulation‑ and indication‑specific maximums (examples: leuprolide acetate injection ≤ 1 mg/day; Lupron Depot/Eligard regimens: 7.5 mg monthly; 22.5 mg/3 months; 30 mg/4 months; 45 mg/6 months; Camcevi ≤ 42 mg/6 months; pediatric depot dosing per Lupron Depot‑Ped table).
    Off‑label uses and evidence: 1. Off‑label uses (e.g., breast/ovarian cancer, salivary gland tumors, gender dysphoria) require prescriber submission of supporting practice guidelines or peer‑reviewed literature when dosing or use exceeds standard label limits; 2. Prescribed regimen should be FDA‑approved or recommended by NCCN when applicable.

    inv-53: Initial therapy dosing examples

    Initial dosing follows product-specific regimens; examples provided below.

    Lupron Depot (IM) regimens: Examples: 3.75 mg monthly; 7.5 mg monthly; 11.25 mg every 3 months; 22.5 mg every 3 months; 30 mg every 4 months; 45 mg every 6 months as appropriate per formulation and indication.
    Eligard (SC) regimens: Examples: 7.5 mg monthly; 22.5 mg every 3 months; 30 mg every 4 months; 45 mg every 6 months per product labeling.
    Camcevi: Example: Camcevi (SC) 42 mg every 6 months for prostate cancer.
    CPP diagnostic and treatment dosing: Diagnostic: leuprolide acetate 20 mcg/kg as needed; Treatment: initial leuprolide acetate (SC) 50 mcg/kg/day with titration by 10 mcg/kg/day if down‑regulation not achieved; pediatric depot formulations dosed per weight (Lupron Depot‑Ped 7.5, 11.25, 15 mg monthly; 11.25, 30 mg every 3 months; 45 mg every 6 months; Fensolvi 45 mg every 6 months).

    inv-54: Initial therapy dosing updates

    Initial therapy updates (documented dosing additions and label-aligned changes).

    Lupron Depot‑Ped 6‑month dosing addition: New 45 mg 6‑month Lupron Depot‑Ped dosage form added for pediatric regimens (per 04.19.23 update).
    Uterine fibroids concurrent therapy and duration: For uterine fibroids, Lupron Depot must be prescribed concurrently with iron therapy per FDA indication; commercial approval duration revised to 3 months (treatment per label limited to three months).

    inv-02: Continuation Therapy

    Covered when ALL of the following are met for continuation

    Continued therapy general: 1. Member is currently receiving the medication via the Centene benefit or documentation supports current treatment (member has received medication for at least 30 days where specified); 2. Member is responding positively to therapy as evidenced by indication‑specific clinical improvement; 3. If request is for a dose increase, the new dose must not exceed the formulation‑specific maximums (e.g., leuprolide acetate injection ≤ 1 mg/day; Eligard/Lupron Depot per regimen limits; Camcevi ≤ 42 mg per 6 months) or the increase must be supported by practice guidelines or peer‑reviewed literature with prescriber evidence;30 days

    inv-55: Continuation Therapy — Criteria for continued therapy

    Criteria for continued therapy

    General continuation node: Member currently receiving medication (or previously met initial criteria) and responding positively; documentation (office notes, labs, or other clinical information) should be provided to support ongoing benefit; dose increases must meet product/indication‑specific maxima or be supported by guidelines/literature with prescriber evidence.
    Approval durations and documentation: Approval durations vary by indication (commonly 12 months for many re‑authorizations); documentation must demonstrate clinical response (e.g., symptom improvement, decreased growth velocity in CPP, or hematologic improvement for fibroid‑related anemia).

    inv-56: Continuation Therapy — General continuation (re-authorization) criteria requiring current therapy, clinical response, and adherence to dose limits

    Continuation (re-authorization) criteria are indication-specific and require current therapy, clinical response, and adherence to dose limits or submission of supporting evidence for higher/off‑label doses.

    Current therapy and response: 1. Member is currently receiving therapy via the benefit or has documentation of prior receipt meeting initial criteria; 2. Member demonstrates clinical response appropriate to indication (e.g., symptom improvement, arrested pubertal progression, decreased growth velocity);
    Dose change requirements: If a dose increase is requested, the new dose must not exceed formulation‑ and indication‑specific maximums (examples: leuprolide acetate injection ≤1 mg/day; Lupron Depot/Eligard maximums per interval; Camcevi ≤42 mg/6 months) or must be supported by practice guidelines/peer‑reviewed literature with prescriber evidence.
    Documentation requirement: Providers must submit supporting documentation (office chart notes, lab results, or other clinical information) demonstrating the member meets continued therapy criteria; failure to submit may lead to denial.

    inv-57: Continuation therapy requirements

    Continuation/renewal approvals require evidence of ongoing clinical benefit and adherence to indication‑specific duration limits.

    Evidence of ongoing benefit: 1. Documentation that member is responding positively to therapy (e.g., symptom improvement, laboratory or imaging evidence where applicable);
    Adherence to duration limits: 1. Continuation approvals must adhere to indication‑specific duration limits (examples: endometriosis total therapy ≤ 12 months; uterine fibroids treatment courses limited to 3 months per label with no reauthorization allowed beyond initial course), and approvals are time‑limited per policy (commonly 12 months for many indications).

    inv-03: Prostate Cancer — Continued Therapy

    Continued therapy for Prostate Cancer (must meet ALL of the following)

    Prostate continued therapy: 1. Member is currently receiving medication via the Centene benefit or documentation supports current use for at least 30 days; 2. Request is for one of the covered products (Camcevi; leuprolide acetate injection; Eligard; Lupron Depot); 3. Member is responding positively to therapy; 4. If request is for a dose increase, the new dose must not exceed product‑specific maximums (leuprolide acetate injection ≤1 mg/day; Eligard/Lupron Depot per interval maxima; Camcevi ≤42 mg/6 months) or be supported by practice guidelines/peer‑reviewed literature (prescriber must submit evidence);30 days

    Prescribed regimen must be FDA‑approved or recommended by NCCN

    inv-04: Endometriosis — Continued Therapy

    Continued therapy for Endometriosis (must meet ALL of the following)

    Endometriosis continued therapy: 1. Member is currently receiving medication via the Centene benefit or previously met initial approval criteria; 2. Request is for Lupron Depot (3.75 mg or 11.25 mg); 3. Member is responding positively to therapy as evidenced by improvement in dysmenorrhea, dyspareunia, pelvic pain, or size of endometrial lesions; 4. Total duration of leuprolide therapy has not exceeded 12 months; 5. If request is for a dose increase, the new dose does not exceed 3.75 mg per month or 11.25 mg per 3 months.

    inv-05: Uterine Fibroids — Re-authorization

    Uterine Fibroids — Re-authorization

    Uterine Fibroids continued therapy: Re-authorization is not permitted. Members must meet the initial approval criteria for each treatment course (approval duration: not applicable).

    inv-06: Central Precocious Puberty — Continued Therapy

    Central Precocious Puberty (must meet ALL of the following)

    CPP continued therapy: 1. Member is currently receiving medication via the Centene benefit or previously met initial approval criteria; 2. Request is for Fensolvi, leuprolide acetate, or Lupron Depot‑Ped; 3. Member is responding positively to therapy as evidenced by decreased growth velocity, cessation of menses, softening of breast tissue/testes, or arrested pubertal progression; 4. Age criteria: female < 11 years OR male < 12 years for continued therapy per policy allowances; 5. If request is for a dose increase, new dose must not exceed pediatric dosing limits (leuprolide SC initial 50 mcg/kg/day titrate by 10 mcg/kg/day if needed; Lupron Depot‑Ped 15 mg/month, 30 mg/3 months, 45 mg/6 months; Fensolvi 45 mg/6 months).

    Approval duration: 12 months

    inv-07: Breast/Ovarian Cancer — Continued Therapy

    Breast and Ovarian Cancer (off‑label) continued therapy (must meet ALL of the following)

    Breast/ovarian cancer continued therapy: 1. Member is currently receiving medication via the Centene benefit or documentation supports current use for at least 30 days for hormone receptor‑positive breast or ovarian cancer; 2. Member is responding positively to therapy; 3. New dose does not exceed 3.75 mg per month or 11.25 mg per 3 months for breast cancer; ovarian cancer dosing limits apply as specified in policy (e.g., up to 7.5 mg/month or alternative multi‑month regimens); 4. If request is for a dose increase, the new dose must meet specified limits or be supported by practice guidelines/peer‑reviewed literature (prescriber must submit supporting evidence).

    Approval duration: 12 months

    inv-08: Gender Dysphoria — Continued Therapy

    Gender Dysphoria / Gender Transition (off‑label) continued therapy

    Gender dysphoria continued therapy: 1. Member is currently receiving medication via the Centene benefit or previously met initial approval criteria; 2. Member is responding positively and continues to meet individualized therapy goals for gender dysphoria/gender transition; 3. If request is for a dose increase, the new dose must be within FDA maximum limits for any FDA‑approved indication or be supported by practice guidelines/peer‑reviewed literature (prescriber must submit supporting evidence); 4. Provider must attest understanding of current State regulations regarding transgender‑related health care and that such care is coverable under the State regulations when applicable;

    Approval duration: 12 months

    inv-09: Salivary Gland Tumors — Continued Therapy

    Salivary gland tumors (off‑label) continued therapy

    Salivary gland tumors continued therapy: 1. Request is for Eligard or Lupron Depot; 2. Member is currently receiving therapy via the Centene benefit or documentation supports at least 30 days of prior therapy; 3. Member is responding positively to therapy; 4. If request is for a dose increase, new dose must be within FDA maximum limits for any FDA‑approved indication or supported by practice guidelines/peer‑reviewed literature (prescriber must submit supporting evidence).

    Approval duration: 12 months

    inv-10: Other Indications — Process

    Other diagnoses/indications handling

    Other indications handling: 1. For drugs on formulary follow the no coverage criteria policy CP PMN.255 (Medicaid) where applicable; 2. For drugs not on formulary follow the non‑formulary policy CP PMN.16 (Medicaid); 3. If the requested use is not specifically listed and prior rules do not authorize coverage, refer to the off‑label use policy CP PMN.53 (Medicaid).

    inv-11: Indication-specific coverage criteria

    Covered when following indication‑specific dosing and duration align with prescribing information and policy requirements.

    Indications covered: Coverage applies for listed indications including advanced prostate cancer, CPP, endometriosis, uterine fibroids (initial preoperative use only), breast and ovarian cancer (off‑label when criteria met), salivary gland tumors (off‑label when criteria met), and gender dysphoria/gender transition when prescriber and documentation requirements are met.
    Uterine fibroids specifics: Lupron Depot for uterine fibroids must be prescribed concurrently with iron therapy per FDA indication and treatment duration is limited to 3 months per label (commercial approval duration revised accordingly); re‑authorization is not permitted beyond initial course.3 months
    Prostate cancer specifics: Eligard and Camcevi are included; redirection to Eligard for Lupron Depot requests through the pharmacy benefit may be applied except where state regulations prohibit redirection (see Appendix F); approvals vary by indication and may be time‑limited (commonly 6–12 months depending on indication).
    CPP specifics: Weight‑based diagnostic and treatment dosing guidance applies (diagnostic 20 mcg/kg; initial treatment 50 mcg/kg/day with titration); pediatric depot formulations and HCPCS/billable unit mappings are provided in appendices.

    inv-12: Updated indication-specific coverage nodes

    Documented indication- and age-specific coverage updates and requirements

    Lupron Depot for uterine fibroids (update): Lupron Depot must be prescribed with concurrent iron therapy per FDA indication; commercial approval duration for uterine fibroids revised to 3 months (treatment per label limited to three months).3 months

    Concurrent iron therapy and duration per FDA label

    Lupron Depot‑Ped 6‑month regimen (update): New 45 mg 6‑month Lupron Depot‑Ped dosage form added for pediatric use and dosing regimens updated accordingly.

    45 mg per 6 months option added

    Endometriosis and uterine leiomyomata age allowance (update): Allowance added permitting use at age 18 when the member is postpubertal per prescribing information.age >= 18 and postpubertal
    Gender dysphoria / gender transition (update): Provider must attest understanding of current State regulations regarding transgender‑related health care and that such care is coverable under State regulations; reference to Movement Advancement Project added in appendices for state coverage confirmation.attestation required
    Prostate cancer routing (update): Eligard FDA‑approved indication updated; Lupron Depot prostate cancer requests via the pharmacy benefit may be redirected to Eligard except in states listed in Appendix F which prohibit redirection.

    Appendix F added for states with anti‑redirection regulations

    Refer to related no-coverage, non‑formulary, and off‑label use policies when the requested diagnosis, age, dosing regimen, or product is not authorized by this policy. Specifically, follow CP PMN.255 for no‑coverage/formulary exclusions (Medicaid), CP PMN.16 for non‑formulary requests (Medicaid), and CP PMN.53 for off‑label uses (Medicaid).

    Non‑FDA‑approved indications that are not specifically addressed in this policy are excluded from coverage unless the request includes sufficient documentation of efficacy and safety consistent with the applicable off‑label use policy (see CP PMN.53 for Medicaid).

    The policy text was updated to remove Lupaneta Pack from the list of covered products because the product is discontinued.

    Note: Lupaneta Pack has been removed from this policy’s product list due to discontinuation.

    Uses or indications not expressly listed under the Diagnoses/Indications sections and not authorized by the referenced formulary or off‑label policies are not covered. In such cases, refer the request to the applicable no‑coverage, non‑formulary, or off‑label use policy (CP PMN.255, CP PMN.16, CP PMN.53) for determination.

    Re‑authorization for uterine fibroids is not permitted under this policy; members must meet the initial approval criteria for any new request.

    No explicit “not medically necessary” statements are included in the provided excerpt. Consult the full policy document for complete Non‑Medically‑Necessary (NMN) clauses and conditions.

    Per the September SDC updates, Commercial and HIM lines of business have been removed from this policy. Coverage determinations for those lines will be governed by a separate policy.

    Coding and Billing

    Coding — not specified in this segmentmixed
    NDC/CPT/HCPCS not listed in this partNo explicit billing codes are provided in this document segment.
    HCPCS mappings by indicationHCPCS
    J9218Leuprolide acetate per mg (used for prostate cancer; central precocious puberty mapping in appendix)
    J9217Lupron Depot/Eligard products (mapped to various month formulations for prostate cancer and salivary gland tumors)
    J1950Leuprolide depot (Lupron Depot 1‑month, pediatric formulations, and breast/ovarian cancer mappings)
    HCPCS Codes referencedHCPCS
    J1950Injection, leuprolide acetate for depot suspension per 3.75 mg
    J9217Leuprolide acetate for depot suspension 7.5 mg
    J9218Leuprolide acetate for depot suspension (designation listed)
    J9219Leuprolide acetate implant 65 mg
    J1951Injection, leuprolide acetate for depot suspension (Fensolvi) 0.25 mg
    J1954Injection, leuprolide acetate for depot suspension (additional code added)
    Appendix D diagnosis-specific HCPCS mappingsmixed
    J9218Mapped for Prostate Cancer and Central Precocious Puberty with billable units and supply day as listed in Appendix D (e.g., Prostate Cancer J9218 billable units 14, supply day 14).
    J9217Mapped for Prostate Cancer and Salivary Gland Tumors with month-formulation billable units and supply day entries in Appendix D (examples: J9217 billable units 3 supply day 84 for 3-month products).
    J1950Mapped for Endometriosis, Uterine Fibroids, CPP pediatric depot formulations, Breast and Ovarian Cancer with billable units and supply day entries in Appendix D.
    Added HCPCS CodesHCPCS
    J1954HCPCS code added (document notes addition; descriptor listed in coding table: Injection, leuprolide acetate for depot suspension (Cipla) 7.5 mg).
    Basal and stimulated LH thresholds for CPP diagnosis
    Basal LH thresholdBasal LH > 0.2–0.3 mIU/mL (assay‑dependent)
    Stimulated LH thresholdLeuprolide‑stimulated LH > 3.3–5 IU/L (assay‑dependent)
    Assay dependence noteThresholds vary by laboratory assay; interpretation must use assay‑specific cutoffs documented by the testing laboratory.
    Billable Units / Supply Day (Appendix D examples)
    Prostate, Leuprolide acetate (per 1 mg) J9218Billable units = 14; Supply day = 14
    Lupron Depot 3‑month / Eligard 22.5 mg J9217Billable units = 3; Supply day = 84
    Lupron Depot‑Ped 45 mg / Fensolvi 45 mgBillable units = 12; Supply day = 168
    Diagnostic leuprolide test dose for CPP
    Diagnostic test dose (leuprolide)20 mcg/kg (as needed) for diagnostic leuprolide stimulation testing
    Initial therapeutic SC exampleLeuprolide acetate (SC) therapeutic initial: 50 mcg/kg per day; titrate upward by 10 mcg/kg/day if down‑regulation is not achieved
    Pediatric depot treatment exampleFensolvi: 45 mg every 6 months; Lupron Depot‑Ped dosing per weight and formulation (7.5–45 mg options)
    Basal luteinizing hormone level units (corrected)
    Reported units (corrected)Basal luteinizing hormone (LH) level units corrected to mIU/mL
    Assay notePolicy clarifies units change from mIU/L to mIU/mL for CPP basal LH reporting
    Use in criteriaBasal LH value >0.2–0.3 mIU/mL used in CPP diagnostic criteria (assay‑dependent)

    Provider Actions and Requirements

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for requests for leuprolide products. Approval criteria enumerate diagnosis-specific, prescriber, dosing, and prior-failure requirements as applicable. Requests for continued therapy also require prior authorization and must meet the indication-specific continued therapy criteria.

    • Prior authorization required for initial and continued therapy.
    • Commercial approval durations and certain concurrent therapy requirements updated per most recent reviews (see policy history).
    • HCPCS code J1954 added to coding appendix for 4Q 2024 updates.
    Step Therapy

    Lupron Depot step / Redirection Risk for Prostate Cancer

    For requests submitted through the pharmacy benefit for Lupron Depot where the indication is prostate cancer, prescribers must document prior failure of Eligard (or provide rationale why Eligard is contraindicated or caused clinically significant adverse effects) before Lupron Depot will be approved, unless the request is for treatment in a state with regulations prohibiting redirection (see Appendix F).

    • Lupron Depot pharmacy‑benefit requests for prostate cancer may be redirected to Eligard unless contraindicated or adverse effects documented.
    • Appendix F lists states where redirection/step therapy for oncology is prohibited.
    Step Therapy

    Step Therapy / Redirection for Oncology

    Requests for oncology indications may be subject to step therapy or redirection to an alternative product (for example, redirection of Lupron Depot requests to Eligard through the pharmacy benefit) except where prohibited by state regulations listed in Appendix F. Providers should be aware that redirection is distinct from medical necessity review and that exceptions must be documented when applicable.

    • Step therapy/redirection may be applied for prostate cancer except in states listed in Appendix F.
    • Redirection does not replace medical necessity review; provide clinical justification for exceptions.
    Documentation Required

    Supportive Documentation Required

    Providers must submit supporting documentation (office chart notes, lab results, prior medication records, prescribing rationale, and any evidence of contraindication or adverse reaction) demonstrating the member meets all approval criteria. Failure to provide sufficient documentation may result in denial.

    • Include documentation showing member is currently receiving the medication (or received it for at least 30 days) and is responding positively when requesting continued therapy.
    • If requesting an exception to step therapy (e.g., avoiding redirection to Eligard), include documentation of contraindication or clinically significant adverse effects to the alternative.
    Prior Authorization

    Lupron Depot (pharmacy benefit) Prior Failure Requirement

    When requesting Lupron Depot through the pharmacy benefit for prostate cancer, the prescriber must attest that Eligard was tried and failed (or provide documentation of contraindication/adverse effects) unless the request originates from a state listed in Appendix F that prohibits redirection. This requirement applies to initial requests submitted via the pharmacy benefit.

    • Document prior trial and failure of Eligard or document contraindication/adverse event.
    • If the state is listed in Appendix F, note the state and reference the applicable regulation to avoid redirection.

    Step Therapy and Therapeutic Alternatives

    Prior step requiredNotes
    Failure of Eligard (prior to approving Lupron Depot via the pharmacy benefit)Required unless Eligard is contraindicated or clinically significant adverse effects are experienced; applies to Lupron Depot requests through the pharmacy benefit.
    Therapeutic alternativeFormulary / PA note
    Preferred alternatives listed in Appendix B (examples include NSAIDs, combined oral contraceptives, progestin-only contraceptives, depot progestin contraceptives)Alternatives may not be formulary for all lines of business and may require prior authorization per formulary status; see Appendix B for complete list.
    Redirection / Preferred productApplicability / exception
    Requests for Lupron Depot for prostate cancer may be redirected to Eligard (preferred product) when processed through the pharmacy benefitRedirection may be applied except in states with regulations prohibiting redirection in cancer (see Appendix F); Appendix F lists affected states and scenarios.
    LimitationRequirement
    Commercial approval duration limited to 3 months for uterine fibroidsLupron Depot must be prescribed concurrently with iron therapy per the FDA indication; treatment per label is limited to three months and commercial approvals reflect this duration.

    Quantity Limits and Formulation Constraints

    Various formulations — formulation-specific maximums and dosing limits
    Eligard / Lupron Depot adult depot limitsEligard/Lupron Depot dosing limits: 7.5 mg monthly; 22.5 mg every 3 months; 30 mg every 4 months; 45 mg every 6 months
    Leuprolide acetate injection (SC) maximumLeuprolide acetate (SC) dosing does not exceed 1 mg per day
    Camcevi maximumCamcevi (leuprolide mesylate) does not exceed 42 mg per 6 months
    Lupron Depot‑Ped pediatric formulationsLupron Depot‑Ped available in 7.5, 11.25, 15 mg (monthly), 11.25, 30 mg (3‑month), and 45 mg (6‑month) formulations
    Billable units and supply day mappings — Appendix D
    Prostate: Leuprolide acetate (per 1 mg) J9218Billable units = 14; Supply day = 14
    Endometriosis/Uterine fibroids: Lupron Depot 1‑month / 3‑month J19501‑month supply day = 28; 3‑month billable units = 3; supply day = 84
    CPP depot pediatric mappingsLupron Depot‑Ped entries: billable units range 2–12 with supply days 28–168 depending on strength (see Appendix D)
    Lupron Depot‑Ped and other depot formulations — billable units and supply day by diagnosis
    Lupron Depot‑Ped 1‑month / 3‑month / 6‑monthExamples: 7.5 mg monthly (billable units 2, supply day 28), 30 mg 3‑month (billable units 8, supply day 84), 45 mg 6‑month (billable units 12, supply day 168)
    Lupron Depot adult depot examplesLupron Depot 3‑month (11.25 mg) billable units = 3; supply day = 84 (endometriosis/fibroids mapping J1950)
    CPP examplesCPP entries in Appendix D show J9218 for leuprolide per 1 mg with billable units 14 and supply day 14 for certain mappings

    Site of Care and Administration

    Billing Rule

    Office billing note — use Appendix D HCPCS mappings for billing

    HCPCS codes, billable units, and supply‑day mappings in Appendix D are provided to support billing by site of care; providers should use those HCPCS mappings when billing but note the policy does not impose additional site‑of‑care restrictions in this section.

    Billing Rule

    Administration site — SC and IM depot formulations may be given in office or outpatient clinic

    Products include both subcutaneous and intramuscular depot formulations (various Lupron Depot, Lupron Depot‑Ped, Camcevi, etc.); site of administration may be office or outpatient clinic as per product labeling and billing guidance.

    Note

    Mixed benefit redirection risk — pharmacy vs medical routing may change coverage pathway

    Prostate cancer requests may be subject to redirection to an alternate product and a different benefit (pharmacy vs medical) depending on routing and state law; providers should verify benefit routing and state redirection rules before submitting PA.

    Background

    Leuprolide acetate and leuprolide mesylate are gonadotropin‑releasing hormone (GnRH) receptor agonists used to suppress pituitary gonadotropin secretion for hormone‑sensitive conditions. They are indicated across multiple formulations for conditions such as advanced prostate cancer, endometriosis, uterine fibroids, and central precocious puberty; depot and injectable formulations provide dosing intervals ranging from monthly to six months.

    Definitions

    Class definition — Leuprolide acetate / mesylate (GnRH receptor agonists)
    ClassLeuprolide acetate and leuprolide mesylate are gonadotropin‑releasing hormone (GnRH) receptor agonists
    Common mechanismActs as a GnRH (gonadotropin‑releasing hormone) agonist to suppress gonadotropin secretion with continuous use
    Typical indicationsUsed for hormone‑sensitive conditions including advanced prostate cancer, endometriosis, uterine fibroids, and central precocious puberty
    CPP abbreviation
    AbbreviationCPP = central precocious puberty
    Context of useCPP used in diagnostic and pediatric dosing sections and Appendix A abbreviations
    Associated dosingCPP dosing includes diagnostic 20 mcg/kg and therapeutic weight‑based regimens with depot pediatric formulations
    GnRH abbreviation
    AbbreviationGnRH = gonadotropin‑releasing hormone
    RoleGnRH is the hypothalamic hormone targeted by GnRH receptor agonists to control sex steroid production
    RelevanceTerm appears in definitions, drug class, and dosing rationale throughout the policy
    CPP definition (detailed)
    DefinitionCentral Precocious Puberty (CPP): early activation of the hypothalamic‑pituitary‑gonadal axis with secondary sexual development before typical age thresholds (female <8 years, male <9 years) and supporting findings such as bone age advancement and elevated LH levels
    Diagnostic componentsDiagnosis confirmed by combination of clinical signs (early secondary sex characteristics), bone age > chronological age by >1 year, and elevated basal or stimulated LH per assay‑specific cutoffs
    Pediatric providerCPP evaluations and treatment should be prescribed by or in consultation with a pediatric endocrinologist
    Postpubertal definition (policy usage)
    Postpubertal meaning in policyPostpubertal: used as an age/physiologic criterion (e.g., endometriosis/fibroids may be allowed at age 18 when member is postpubertal per prescribing information)
    ApplicationPostpubertal status is required for certain age allowances in endometriosis and uterine leiomyomata coverage nodes
    DocumentationPrescribers must document postpubertal status when relying on age‑based allowances